JPH08277209A - Revitalizing hair tonic - Google Patents
Revitalizing hair tonicInfo
- Publication number
- JPH08277209A JPH08277209A JP7082122A JP8212295A JPH08277209A JP H08277209 A JPH08277209 A JP H08277209A JP 7082122 A JP7082122 A JP 7082122A JP 8212295 A JP8212295 A JP 8212295A JP H08277209 A JPH08277209 A JP H08277209A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- minoxidil
- ether
- hair restorer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001256 tonic effect Effects 0.000 title abstract description 5
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 17
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 13
- JAUFWPNLLLUYNV-UHFFFAOYSA-N 3-(16-methylheptadecoxy)propane-1,2-diol Chemical compound CC(C)CCCCCCCCCCCCCCCOCC(O)CO JAUFWPNLLLUYNV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims abstract description 9
- ASGSROHYBOETMM-UHFFFAOYSA-N alpha-monoisostearyl glycerylether Natural products CC(C)CCCCCCCCCCCCCCCCC(=O)OCC(O)CO ASGSROHYBOETMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000011187 glycerol Nutrition 0.000 claims abstract description 7
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 24
- 229960003632 minoxidil Drugs 0.000 claims description 24
- -1 aliphatic monoalkylether Chemical class 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000006210 lotion Substances 0.000 abstract description 7
- 238000009472 formulation Methods 0.000 abstract description 5
- 239000000443 aerosol Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 3
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 4
- 229960003720 enoxolone Drugs 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229930007845 β-thujaplicin Natural products 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 2
- 229960003517 isothipendyl Drugs 0.000 description 2
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- UYZQWKKNVBJVOF-UHFFFAOYSA-N 1-decoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCC UYZQWKKNVBJVOF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 244000084296 Hernandia moerenhoutiana Species 0.000 description 1
- 235000010044 Hernandia moerenhoutiana Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- PXGPQCBSBQOPLZ-UHFFFAOYSA-N butanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCC(O)=O PXGPQCBSBQOPLZ-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、ミノキシジルの経皮吸
収性を増大させた育毛剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a hair-growth agent having increased transdermal absorbability of minoxidil.
【0002】[0002]
【従来の技術】ミノキシジルは化学名を6−(1−ピペ
リジニル)−2,4−ピリミジンジアミン−3−オキサ
イドと称し、米国特許公報第4139619号に育毛剤
としての適用が述べられている。その米国特許公報中に
基剤成分としてプロピレングリコールを配合した処方例
などが記載されている。しかし、皮膚には薬物透過に対
する抵抗性が備わっているため、ミノキシジルを外用剤
として用いた場合、薬効発現に十分な量が吸収されにく
いという欠点があった。そのため、近年ミノキシジルの
経皮吸収性を製剤的に向上させる試みが行われてきた
が、これまで公知になっている製剤ではミノキシジルの
経皮吸収性が悪く、程度の異なる各種の脱毛症に対して
十分な効果が得られていなかった。Minoxidil has a chemical name of 6- (1-piperidinyl) -2,4-pyrimidinediamine-3-oxide, and its application as a hair restorer is described in U.S. Pat. No. 4,139,619. In the US patent publication, a formulation example in which propylene glycol is added as a base component is described. However, since the skin has resistance to drug permeation, when minoxidil is used as an external preparation, there is a drawback that it is difficult to absorb a sufficient amount to exert its drug effect. Therefore, in recent years, attempts have been made to improve the transdermal absorbability of minoxidil as a preparation, but the transdermal absorbability of minoxidil has been poor in the hitherto known preparations, and for various types of alopecia of various types. Was not sufficiently effective.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は上記事
情を鑑み、ミノキシジルの経皮吸収性を増大させ、薬効
発現に十分な量のミノキシジルが経皮吸収される育毛剤
を提供することにある。SUMMARY OF THE INVENTION In view of the above circumstances, an object of the present invention is to provide a hair-growth agent which increases the transdermal absorbability of minoxidil, and in which a sufficient amount of minoxidil to exert a drug effect is transdermally absorbed. is there.
【0004】[0004]
【課題を解決するための手段】本発明者らは、鋭意研究
の結果、脂肪族多価アルコールのモノアルキルエーテル
がミノキシジルの経皮吸収性を著しく高めることを見い
だし、本発明を完成した。すなわち、本発明はミノキシ
ジルおよび脂肪族多価アルコールのモノアルキルエーテ
ルを含有することを特徴とする育毛剤である。As a result of earnest research, the present inventors have found that a monoalkyl ether of an aliphatic polyhydric alcohol significantly enhances the transdermal absorbability of minoxidil, and completed the present invention. That is, the present invention is a hair restorer characterized by containing minoxidil and a monoalkyl ether of an aliphatic polyhydric alcohol.
【0005】本発明において、脂肪族多価アルコールと
は炭素数2個から6個で、2価または3価のアルコール
である。脂肪族多価アルコールとして好ましいものにグ
リセリン、ヘキサントリオール、エチレングリコール、
プロピレングリコール、1,4−ブタンジオール、トリ
エチレングリコール、ジエチレングリコールなどがあげ
られ、最も好ましいものとしてグリセリンがあげられ
る。また、脂肪族多価アルコールとエーテル結合を為す
アルキル基として好ましいのは炭素数8から24の直鎖
状または分岐鎖状のアルキル基である。炭素鎖が8より
短くなると皮膚刺激性が増し、外用剤として好ましくな
く、炭素鎖が24より長くなると流動性が悪くなり、製
剤化が困難になる。アルキル基として好ましいものにオ
クチル基、ノニル基、デシル基、ドデシル基、テトラデ
シル基、セチル基、ステアリル基、イソステアリル基、
エイコサニル基、ドコサニル基などがあげられ、最も好
ましいものとしてイソステアリル基があげられる。In the present invention, the aliphatic polyhydric alcohol is a divalent or trivalent alcohol having 2 to 6 carbon atoms. Glycerin, hexanetriol, ethylene glycol, and the like are preferable as the aliphatic polyhydric alcohol.
Propylene glycol, 1,4-butanediol, triethylene glycol, diethylene glycol and the like can be mentioned, and glycerin is most preferable. Further, the alkyl group which forms an ether bond with the aliphatic polyhydric alcohol is preferably a linear or branched alkyl group having 8 to 24 carbon atoms. When the carbon chain is shorter than 8, the skin irritation is increased and it is not preferable as an external preparation, and when the carbon chain is longer than 24, the fluidity is deteriorated and the formulation becomes difficult. Octyl group, nonyl group, decyl group, dodecyl group, tetradecyl group, cetyl group, stearyl group, isostearyl group to the preferred alkyl group,
Examples thereof include eicosanyl group and docosanyl group, and the most preferable one is isostearyl group.
【0006】脂肪族多価アルコールにおいて、アルキル
基とエーテル結合を為す水酸基は何れの部位の水酸基で
も構わないが、脂肪鎖の末端に位置する水酸基とエーテ
ル結合したものが最も好ましい。In the aliphatic polyhydric alcohol, the hydroxyl group forming an ether bond with the alkyl group may be a hydroxyl group at any site, but a hydroxyl group at the terminal of the fatty chain with an ether bond is most preferred.
【0007】本発明中の脂肪族多価アルコールのモノア
ルキルエーテルが、外用剤として用いた場合に、高い安
全性を持ったもので無ければならないのは当然のことで
ある。As a matter of course, the monoalkyl ether of the aliphatic polyhydric alcohol used in the present invention must have high safety when used as an external preparation.
【0008】本発明では、ミノキシジルの配合量は製剤
全体に対して0.1〜5重量%が好ましく、さらに好ま
しくは0.5〜2重量%である。脂肪族多価アルコール
のモノアルキルエーテルの配合量は1〜20重量%が好
ましく、さらに好ましくは2〜10重量%である。また
その他の成分としては通常育毛剤に用いられる賦形剤、
血管拡張剤(塩化カルプロニウム、ニコチン酸ベンジ
ル、センブリ抽出液、オタネニンジンエキス、ビタミン
Eアセテート、トウガラシチンキなど)、副腎皮質ホル
モン(酢酸ヒドロコルチゾン、酪酸プロピオン酸ヒドロ
コルチゾンなど)、抗ヒスタミン剤(塩酸ジフェンヒド
ラミン、塩酸イソチペンジルなど)、抗炎症剤(グリチ
ルレチン酸、グアイアズレンなど)、角質溶解剤(尿
素、サリチル酸など)、殺菌剤(グルコン酸クロルヘキ
シジン、イソプロピルメチルフェノール、第4級アンモ
ニウム塩、ヒノキチオール、ピロクトンオラミンな
ど)、保湿剤(ヒアルロン酸ナトリウム、グリセリン、
コンドロイチン硫酸など)、各種動植物(イチイ、ボタ
ンピ、カンゾウ、オトギリソウ、附子、ビワ、カワラヨ
モギ、コンフリー、アシタバ、サフラン、サンシシ、ロ
ーズマリー、セージ、モッコウ、セイモッコウ、ホッ
プ、プラセンタなど)の抽出物、ビタミン類(酢酸レチ
ノール、塩酸ピリドキシン、アスコルビン酸、硝酸チア
ミン、シアノコバラミン、ビオチンなど)、油分(ミリ
スチン酸イソプロピル、パルミチン酸イソプロピル、ス
クワラン、流動パラフィン、レシチンなど)、界面活性
剤(ポリオキシエチレンソルビタン脂肪酸エステル、ソ
ルビタン脂肪酸エステル、ポリオキシエチレン脂肪酸エ
ステル、グリセリン脂肪酸エステル、プロピレングリコ
ール脂肪酸エステル、ポリオキシエチレン硬化ヒマシ油
など)、多価アルコール(プロピレングリコール、1,
3−ブタンジオール、マクロゴール、ジプロピレングリ
コールなど)、精油(メントール、カンフルなど)、抗
酸化剤(ジブチルヒドロキシトルエン、イソプロピルガ
レートなど)、金属イオン封鎖剤(エチレンジアミンテ
トラアセテートまたはその塩)、色素、香料などを、本
発明の組成物の効果を損なわない範囲で配合することが
できる。In the present invention, the content of minoxidil is preferably 0.1 to 5% by weight, more preferably 0.5 to 2% by weight, based on the whole preparation. The compounding amount of the monoalkyl ether of the aliphatic polyhydric alcohol is preferably 1 to 20% by weight, more preferably 2 to 10% by weight. As other ingredients, excipients usually used in hair restorers,
Vasodilators (carpronium chloride, benzyl nicotinate, senburi extract, ginseng extract, vitamin E acetate, capsicum tincture, etc.), corticosteroids (hydrocortisone acetate, hydrocortisone propionate butyrate, etc.), antihistamines (diphenhydramine hydrochloride, isothipendyl hydrochloride, etc.) , Anti-inflammatory agents (glycyrrhetinic acid, guaizulene, etc.), keratolytic agents (urea, salicylic acid, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, quaternary ammonium salts, hinokitiol, piroctone olamine, etc.), moisturizers (Sodium hyaluronate, glycerin,
Chondroitin sulphate, etc.), extracts of various plants and animals (yew, button pipi, licorice, St. John's wort, konjac, loquat, sagebrush, comfrey, ashitaba, saffron, sardine, rosemary, sage, mokko, samokko, hops, placenta, etc.), vitamins Kinds (retinol acetate, pyridoxine hydrochloride, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, etc.), oil (isopropyl myristate, isopropyl palmitate, squalane, liquid paraffin, lecithin, etc.), surfactant (polyoxyethylene sorbitan fatty acid ester, Sorbitan fatty acid ester, polyoxyethylene fatty acid ester, glycerin fatty acid ester, propylene glycol fatty acid ester, polyoxyethylene hydrogenated castor oil, etc.), polyhydric alcohol Le (propylene glycol, 1,
3-butanediol, macrogol, dipropylene glycol, etc.), essential oils (menthol, camphor, etc.), antioxidants (dibutylhydroxytoluene, isopropyl gallate, etc.), sequestering agents (ethylenediaminetetraacetate or its salts), dyes, Fragrances and the like can be added within a range that does not impair the effects of the composition of the present invention.
【0009】本発明の育毛剤はローション剤、トニック
剤、クリーム剤、軟膏剤、エアゾール剤などの外用製剤
を常法に従って製造することができる。The hair restorer of the present invention can be prepared according to a conventional method from external preparations such as lotions, tonics, creams, ointments and aerosols.
【0010】本発明の育毛剤は、1日1〜数回適量を頭
皮に塗布して使用する。The hair restorer of the present invention is applied to the scalp in an appropriate amount once to several times a day for use.
【0011】[0011]
【発明の効果】後記試験例から明らかなように、本発明
によりミノキシジルの経皮吸収性を高めた育毛剤を提供
することが可能になった。As is apparent from the test examples described below, the present invention has made it possible to provide a hair-growing agent with improved transdermal absorbability of minoxidil.
【0012】[0012]
【実施例】以下、実施例および試験例に基づいて本発明
を詳細に説明する。EXAMPLES The present invention will be described in detail below based on examples and test examples.
【0013】実施例1 エタノール80重量部にミノキシジル0.5重量部、α
−モノイソステアリルグリセリルエーテル2重量%、精
製水17.5重量部を加えて撹拌溶解し、ローションタ
イプの育毛剤を調製した。Example 1 80 parts by weight of ethanol, 0.5 parts by weight of minoxidil, α
-2% by weight of monoisostearyl glyceryl ether and 17.5 parts by weight of purified water were added and dissolved by stirring to prepare a lotion type hair restorer.
【0014】実施例1記載の調整方法に準じ、表1に示
す処方で実施例2〜4および対照例1、2の育毛剤を調
製した。According to the adjusting method described in Example 1, the hair-growing agents of Examples 2 to 4 and Control Examples 1 and 2 were prepared according to the formulations shown in Table 1.
【0015】[0015]
【表1】 [Table 1]
【0016】実施例5 精製水42.7重量部にカルボキシビニルポリマー0.
4重量部を撹拌しながら分散させた。これに、エタノー
ル40重量部、1,3−ブタンジオール5重量部、ミノ
キシジル1重量部、α−モノイソステアリルグリセリル
エーテル10重量部、L−メントール0.5重量部およ
びジイソプロパノールアミン0.4重量部を撹拌溶解さ
せた液を添加し、撹拌混合して、ゲルタイプの育毛剤を
調製した。Example 5 42.7 parts by weight of purified water were mixed with 0.
4 parts by weight were dispersed with stirring. 40 parts by weight of ethanol, 5 parts by weight of 1,3-butanediol, 1 part by weight of minoxidil, 10 parts by weight of α-monoisostearyl glyceryl ether, 0.5 part by weight of L-menthol and 0.4 part by weight of diisopropanolamine. A solution in which the parts were dissolved by stirring was added and mixed by stirring to prepare a gel-type hair restorer.
【0017】実施例6 ポリオキシエチレン(20)ソルビタンモノステアレー
ト5重量部、ソルビタンモノステアレート3重量部、セ
タノール2重量部、ステアリルアルコール2重量部、流
動パラフィン10重量部およびビタミンEアセテート
0.2重量部、α−モノイソステアリルグリセリルエー
テル2重量部を加温しながら混合溶解した。別に、ミノ
キシジル1重量部、ヒノキチオール0.1重量部、グリ
チルレチン酸0.2重量部、ジブチルヒドロキシトルエ
ン0.05重量部、エチレンジアミンテトラアセテート
−2ナトリウム塩0.05重量部、パラオキシ安息香酸
メチル0.05重量部、精製水74.35重量部を加温
しながら溶解撹拌した液を加え、混合撹拌しながら室温
まで冷却し、クリームタイプの育毛剤を調製した。Example 6 Polyoxyethylene (20) sorbitan monostearate 5 parts by weight, sorbitan monostearate 3 parts by weight, cetanol 2 parts by weight, stearyl alcohol 2 parts by weight, liquid paraffin 10 parts by weight and vitamin E acetate 0. 2 parts by weight and 2 parts by weight of α-monoisostearyl glyceryl ether were mixed and dissolved while heating. Separately, 1 part by weight of minoxidil, 0.1 part by weight of hinokitiol, 0.2 part by weight of glycyrrhetinic acid, 0.05 part by weight of dibutylhydroxytoluene, 0.05 part by weight of ethylenediaminetetraacetate-2 sodium salt, methyl paraoxybenzoate of 0.1 part by weight. A solution in which 05 parts by weight and 74.35 parts by weight of purified water were dissolved and stirred while heating was added, and the mixture was cooled to room temperature with mixing and stirring to prepare a cream type hair restorer.
【0018】実施例7 ミノキシジル2重量部、パントテニールエチルエーテル
0.1重量部、センブリエキス0.1重量部、α−モノ
イソステアリルグリセリルエーテル2重量部、ポリオキ
シエチレン硬化ヒマシ油0.5重量部、エタノール60
重量部、精製水35.3重量部を撹拌溶解して、ローシ
ョンタイプの育毛剤を調製した。Example 7 Minoxidil 2 parts by weight, pantotenyl ethyl ether 0.1 parts by weight, assembly extract 0.1 parts by weight, α-monoisostearyl glyceryl ether 2 parts by weight, polyoxyethylene hydrogenated castor oil 0.5 parts by weight. Part, ethanol 60
A lotion type hair restorer was prepared by stirring and dissolving 3 parts by weight of purified water and 35.3 parts by weight of purified water.
【0019】実施例8 ミノキシジル5重量部、プロピレングリコール10重量
部、α−モノイソステアリルグリセリルエーテル10重
量部、エタノール65重量部、精製水10重量部を混合
溶解して、ローションタイプの育毛剤を調製した。Example 8 5 parts by weight of minoxidil, 10 parts by weight of propylene glycol, 10 parts by weight of α-monoisostearyl glyceryl ether, 65 parts by weight of ethanol and 10 parts by weight of purified water were mixed and dissolved to give a lotion type hair restorer. Prepared.
【0020】実施例9 ミノキシジル0.5重量部、グリセリン2重量部、ポリ
オキシエチレン(20)ポリオキシプロピレン(6)デ
シルテトラデシルエーテル2重量部、セイモッコウエキ
ス1重量部、ニンジンエキス0.1重量部、α−モノイ
ソステアリルグリセリルエーテル10重量部、エタノー
ル60重量部および精製水24.4重量部を撹拌溶解
し、ローションタイプの育毛剤を調製した。Example 9 0.5 part by weight of minoxidil, 2 parts by weight of glycerin, 2 parts by weight of polyoxyethylene (20) polyoxypropylene (6) decyl tetradecyl ether, 1 part by weight of gypsum extract, and carrot extract 0.1. By weight, 10 parts by weight of α-monoisostearyl glyceryl ether, 60 parts by weight of ethanol and 24.4 parts by weight of purified water were dissolved by stirring to prepare a lotion-type hair restorer.
【0021】実施例10 ミノキシジル2重量部、エチニルエストラジオール0.
0008重量部、トウガラシチンキ0.5重量部、ニコ
チン酸アミド0.2重量部、ポリオキシエチレン(6)
モノオレエート0.5重量部、ジプロピレングリコール
4重量部、α−モノイソステアリルグリセリルエーテル
5重量部、ハッカ油0.01重量部、ジブチルヒドロキ
シトルエン0.005重量部、エタノール60重量部、
精製水27.7842重量部を撹拌溶解し、ローション
タイプの育毛剤を調製した。Example 10 Minoxidil 2 parts by weight, ethinyl estradiol 0.
0008 parts by weight, capsicum tincture 0.5 parts by weight, nicotinic acid amide 0.2 parts by weight, polyoxyethylene (6)
0.5 parts by weight of monooleate, 4 parts by weight of dipropylene glycol, 5 parts by weight of α-monoisostearyl glyceryl ether, 0.01 part by weight of peppermint oil, 0.005 part by weight of dibutylhydroxytoluene, 60 parts by weight of ethanol,
27.7842 parts by weight of purified water was dissolved by stirring to prepare a lotion type hair restorer.
【0022】実施例11 ミノキシジル1重量部、イソプロピルメチルフェノール
0.05重量部、1,3−ブタンジオール5重量部、α
−モノイソステアリルグリセリルエーテル5重量部、ポ
リオキシエチレン(20)硬化ヒマシ油0.5重量部、
エタノール55重量部および精製水33.45重量部を
撹拌溶解した。この液50重量部をエアゾール缶に入
れ、ジメチルエーテル50重量部を加圧充填し、エアゾ
ールタイプの育毛剤を調製した。Example 11 Minoxidil 1 part by weight, isopropylmethylphenol 0.05 part by weight, 1,3-butanediol 5 parts by weight, α
5 parts by weight of monoisostearyl glyceryl ether, 0.5 parts by weight of polyoxyethylene (20) hydrogenated castor oil,
55 parts by weight of ethanol and 33.45 parts by weight of purified water were dissolved by stirring. 50 parts by weight of this solution was placed in an aerosol can, and 50 parts by weight of dimethyl ether was charged under pressure to prepare an aerosol type hair restorer.
【0023】実施例12 ミノキシジル2重量部、グリチルレチン酸0.1重量
部、ヒノキチオール0.1重量部、ビタミンEアセテー
ト0.2重量部、パントテニールエチルエーテル0.1
5重量部、塩酸イソチペンジル0.5重量部、塩酸ピリ
ドキシン0.1重量部、プラセンタエキス0.1重量
部、ミリスチン酸オクチルドデシル0.5重量部、L−
メントール0.05重量部、グリセリルモノオレエート
1重量部、ソルビタンモノラウレート1重量部、α−モ
ノイソステアリルグリセリルエーテル20重量部、エタ
ノール50重量部および精製水24.2重量部を撹拌溶
解してローションタイプの育毛剤を調製した。Example 12 2 parts by weight of minoxidil, 0.1 part by weight of glycyrrhetinic acid, 0.1 part by weight of hinokitiol, 0.2 part by weight of vitamin E acetate, 0.1 part of pantotenyl ethyl ether.
5 parts by weight, isothipendyl hydrochloride 0.5 part by weight, pyridoxine hydrochloride 0.1 part by weight, placenta extract 0.1 part by weight, octyldodecyl myristate 0.5 part by weight, L-
0.05 parts by weight of menthol, 1 part by weight of glyceryl monooleate, 1 part by weight of sorbitan monolaurate, 20 parts by weight of α-monoisostearyl glyceryl ether, 50 parts by weight of ethanol and 24.2 parts by weight of purified water were dissolved by stirring. To prepare a lotion type hair restorer.
【0024】実施例13 ステアリン酸2重量部、セタノール1.5重量部、白色
ワセリン3重量部、ラノリンアルコール2重量部、ポリ
オキシエチレン(10)モノオレエート2重量部、α−
モノイソステアリルグリセリルエーテル5重量部、ビタ
ミンEアセテート0.2重量部を加熱しながら混合溶解
した。これに、ミノキシジル0.5重量部、グリチルレ
チン酸0.2重量部、パラオキシ安息香酸メチル0.0
5重量部、エチレンジアミンテトラアセテート−2ナト
リウム塩0.05重量部、プロピレングリコール10重
量部、精製水73.5重量部を加熱溶解した液を加え、
混合しながら室温まで冷却し、乳液タイプの育毛剤を調
製した。Example 13 2 parts by weight of stearic acid, 1.5 parts by weight of cetanol, 3 parts by weight of white petrolatum, 2 parts by weight of lanolin alcohol, 2 parts by weight of polyoxyethylene (10) monooleate, α-
5 parts by weight of monoisostearyl glyceryl ether and 0.2 parts by weight of vitamin E acetate were mixed and dissolved while heating. 0.5 parts by weight of minoxidil, 0.2 parts by weight of glycyrrhetinic acid, and 0.0 parts of methyl paraoxybenzoate.
5 parts by weight, 0.05 parts by weight of ethylenediamine tetraacetate-2 sodium salt, 10 parts by weight of propylene glycol, and 73.5 parts by weight of purified water were added and dissolved in a liquid,
While mixing, the mixture was cooled to room temperature to prepare an emulsion type hair restorer.
【0025】試験例[ミノキシジルの経皮吸収試験] ウイスター系ラット(7週齢,オス)の腹部皮膚を摘出
し、ガラス製拡散セル(有効面積0.95cm2)にレ
シーバー側が皮膚の裏面に接するように装着した。レシ
ーバーにはpH7.4のリン酸緩衝液3mlを加え、循
環水により37℃に保つようにした。皮膚の表面側は開
放状態とし、実施例1〜4および対照例1、2の試料を
5μl塗布し、レシーバー溶液中に透過してくるミノキ
シジル量を高速液体クロマトグラフ法により測定した。
試験結果は試験開始24時間後の透過量について、比較
例サンプルを100%とした場合の実施例サンプルの透
過量の比率(実施例1および実施例2については比較例
1と、実施例3および実施例4については比較例2とそ
れぞれ比較)で表した。その結果を表2に示す。Test Example [Minoxidil Transdermal Absorption Test] The abdominal skin of Wistar rats (7 weeks old, male) was excised, and the receiver side was brought into contact with the back surface of the skin in a glass diffusion cell (effective area 0.95 cm 2 ). So it was installed. To the receiver, 3 ml of pH 7.4 phosphate buffer was added, and the temperature was kept at 37 ° C by circulating water. The surface side of the skin was left open, 5 μl of the samples of Examples 1 to 4 and Controls 1 and 2 were applied, and the amount of minoxidil permeated into the receiver solution was measured by a high performance liquid chromatography method.
The test result shows that the ratio of the amount of permeation of the sample of the example when the amount of the sample of the comparative example was 100% with respect to the amount of permeation 24 hours after the start of the test (for example 1 and example 2, comparative example 1, example 3 and Example 4 was described as Comparative Example 2). The results are shown in Table 2.
【0026】[0026]
【表2】 [Table 2]
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 47/04 A61K 47/04 E 47/14 47/14 E (72)発明者 漆崎 文男 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display location A61K 47/04 A61K 47/04 E 47/14 47/14 E (72) Inventor Fumio Urushizaki Tokyo 3-24-1 Takada, Toshima-ku, Taisho Pharmaceutical Co., Ltd.
Claims (3)
ルのモノアルキルエーテルを含有することを特徴とする
育毛剤。1. A hair restorer containing minoxidil and a monoalkyl ether of an aliphatic polyhydric alcohol.
る請求項1記載の育毛剤。2. The hair restorer according to claim 1, wherein the aliphatic polyhydric alcohol is glycerin.
ーテルがα−モノイソステアリルグリセリルエーテルで
ある請求項1記載の育毛剤。3. The hair restorer according to claim 1, wherein the monoalkyl ether of the aliphatic polyhydric alcohol is α-monoisostearyl glyceryl ether.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7082122A JPH08277209A (en) | 1995-04-07 | 1995-04-07 | Revitalizing hair tonic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7082122A JPH08277209A (en) | 1995-04-07 | 1995-04-07 | Revitalizing hair tonic |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08277209A true JPH08277209A (en) | 1996-10-22 |
Family
ID=13765617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7082122A Pending JPH08277209A (en) | 1995-04-07 | 1995-04-07 | Revitalizing hair tonic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH08277209A (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032417A1 (en) * | 1997-01-23 | 1998-07-30 | Taisho Pharmaceutical Co., Ltd. | Persistent hair tonic |
JPH10265343A (en) * | 1997-01-23 | 1998-10-06 | Taisho Pharmaceut Co Ltd | Sustained release hair growing agent |
WO2001076540A1 (en) * | 2000-04-07 | 2001-10-18 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulant compositions |
JP2005206536A (en) * | 2004-01-23 | 2005-08-04 | Kao Corp | Hair-growing agent |
JP2006022091A (en) * | 2004-06-09 | 2006-01-26 | Dai Ichi Seiyaku Co Ltd | Composition for growing hair |
JP2007320873A (en) * | 2006-05-31 | 2007-12-13 | Mandom Corp | Antiseptic sterilizable composition |
JP2009215323A (en) * | 2004-06-09 | 2009-09-24 | Daiichi Sankyo Healthcare Co Ltd | New hair growing composition |
JP2016138094A (en) * | 2015-01-23 | 2016-08-04 | 大正製薬株式会社 | External composition |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
JP2020007280A (en) * | 2018-07-11 | 2020-01-16 | 花王株式会社 | Hair restorer |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
-
1995
- 1995-04-07 JP JP7082122A patent/JPH08277209A/en active Pending
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032417A1 (en) * | 1997-01-23 | 1998-07-30 | Taisho Pharmaceutical Co., Ltd. | Persistent hair tonic |
JPH10265343A (en) * | 1997-01-23 | 1998-10-06 | Taisho Pharmaceut Co Ltd | Sustained release hair growing agent |
AU729411B2 (en) * | 1997-01-23 | 2001-02-01 | Taisho Pharmaceutical Co., Ltd. | Sustained release hair growth preparation |
US6255313B1 (en) | 1997-01-23 | 2001-07-03 | Taisho Pharmaceutical Co., Ltd. | Sustained release hair growth composition |
WO2001076540A1 (en) * | 2000-04-07 | 2001-10-18 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulant compositions |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
JP2005206536A (en) * | 2004-01-23 | 2005-08-04 | Kao Corp | Hair-growing agent |
JP2009215323A (en) * | 2004-06-09 | 2009-09-24 | Daiichi Sankyo Healthcare Co Ltd | New hair growing composition |
JP2006022091A (en) * | 2004-06-09 | 2006-01-26 | Dai Ichi Seiyaku Co Ltd | Composition for growing hair |
JP2007320873A (en) * | 2006-05-31 | 2007-12-13 | Mandom Corp | Antiseptic sterilizable composition |
US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
JP2016138094A (en) * | 2015-01-23 | 2016-08-04 | 大正製薬株式会社 | External composition |
US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
JP2020007280A (en) * | 2018-07-11 | 2020-01-16 | 花王株式会社 | Hair restorer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08277209A (en) | Revitalizing hair tonic | |
JPH07316023A (en) | Hair tonic | |
JP4940527B2 (en) | Sustainable hair growth composition | |
JP4554805B2 (en) | Hair nourishing | |
JP2001288043A (en) | Composition for scalp and hair | |
JPH10218737A (en) | Hair grower | |
WO1989002731A1 (en) | Hair tonic | |
JPH07316022A (en) | Hair tonic | |
JP2810040B2 (en) | Hair restorer for scalp and hair | |
JP2001288048A (en) | Composition for scalp and hair | |
JP2001288046A (en) | Composition for scalp and hair | |
JPH04305519A (en) | Skin humectant for external use | |
JPH10279437A (en) | Hair cosmetic | |
JP2001288045A (en) | Composition for scalp and hair | |
JPH09241137A (en) | Hair crowing and restoring agent | |
JPH08113516A (en) | Composition for scalp | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
JPH0971513A (en) | Hair tonic | |
JP2969866B2 (en) | Hair growth agent | |
EP0679385B1 (en) | Hair revitalizing composition | |
JPH0640858A (en) | Hair tonic | |
JPH07206647A (en) | Hair tonic | |
JPH0920613A (en) | Cosmetic | |
JP2004059470A (en) | Hair tonic | |
JP2814090B2 (en) | Hair restoration |